Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group

Nature Chemical Biology

Volumn 9, Issue 5, 2013, Pages 319-325

  Lobera, Mercedes ^a   Madauss, Kevin P ^b   Pohlhaus, Denise T ^b   Wright, Quentin G ^a,d   Trocha, Mark ^a   Schmidt, Darby R ^a,e   Baloglu, Erkan ^a,f   Trump, Ryan P ^b   Head, Martha S ^b   Hofmann, Glenn A ^b   Murray Thompson, Monique ^b   Schwartz, Benjamin ^b   Chakravorty, Subhas ^b   Wu, Zining ^b   Mander, Palwinder K ^c   Kruidenier, Laurens ^c   Reid, Robert A ^b   Burkhart, William ^b   Turunen, Brandon J ^b   Rong, James X ^b,g   Wagner, Craig ^b   Moyer, Mary B ^b   Wells, Carrow ^b   Hong, Xuan ^b   Moore, John T ^b   Williams, Jon D ^b   Soler, Dulce ^a,h   Ghosh, Shomir ^a   Nolan, Michael A ^a   more..

^a Tempero Pharmaceuticals   (United States)

^b GLAXOSMITHKLINE   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d Verastem Oncology Chief Medical Officer   (United States)

^e Forma Therapeutics   (United States)

^f Karyopharm Therapeutics   (United States)

^g ELI LILLY AND COMPANY   (United States)

^h PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 2A; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; OXADIAZOLE DERIVATIVE; TRIFLUOROMETHYLOXADIAZOLE; UNCLASSIFIED DRUG; ZINC;

ARTICLE; BINDING AFFINITY; CATALYSIS; CHELATION; CONTROLLED STUDY; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; INHIBITION KINETICS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; ORGANOMETALLIC COMPOUNDS; OXADIAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP; ZINC;

EID: 84879092346     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1223     Document Type: Article

References (33)

1. Bradner, J.E. et al. Chemical phylogenetics of histone deacetylases. Nat. Chem. Biol. 6, 238-243 (2010).
2. Fischle, W. et al. Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo. J. Biol. Chem. 276, 35826-35835 (2001).
3. Choudhary, C. et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-840 (2009).
4. Kim, S.C. et al. Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol. Cell 23, 607-618 (2006).
5. Yuan, Z., Peng, L., Radhakrishnan, R. & Seto, E. Histone deacetylase 9 (HDAC9) regulates the functions of the ATDC (TRIM29) protein. J. Biol. Chem. 285, 39329-39338 (2010).
6. Fischle, W. et al. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol. Cell 9, 45-57 (2002).
7. McKinsey, T.A., Zhang, C.L. & Olson, E.N. Activation of the myocyte enhancer factor-2 transcription factor by calcium/calmodulin-dependent protein kinase-stimulated binding of 14-3-3 to histone deacetylase 5. Proc. Natl. Acad. Sci. USA 97, 14400-14405 (2000).
8. Zhang, C.L. et al. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110, 479-488 (2002).
9. Verdin, E., Dequiedt, F. & Kasler, H.G. Class II histone deacetylases: versatile regulators. Trends Genet. 19, 286-293 (2003).
10. Arrowsmith, C.H., Bountra, C., Fish, P.V., Lee, K. & Schapira, M. Epigenetic protein families: a new frontier for drug discovery. Nat. Rev. Drug Discov. 11, 384-400 (2012).
11. Brockschmidt, F.F. et al. Susceptibility variants on chromosome 7p21.1 suggest HDAC9 as a new candidate gene for male-pattern baldness. Br. J. Dermatol. 165, 1293-1302 (2011).
12. Mielcarek, M. et al. SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease. PLoS One 6, e27746 (2011).
13. Quinti, L. et al. Evaluation of histone deacetylases as drug targets in Huntington's disease models. Study of HDACs in brain tissues from R6/2 and CAG140 knock-in HD mouse models and human patients and in a neuronal HD cell model. PLoS Curr. 2, pii:RRN1172 (2010).
14. Berdeaux, R. et al. SIK1 is a class II HDAC kinase that promotes survival of skeletal myocytes. Nat. Med. 13, 597-603 (2007).
15. Tao, R. et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat. Med. 13, 1299-1307 (2007).
16. International Stroke Genetics Consortium (ISGC). et al. Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke. Nat. Genet. 44, 328-333 (2012).
17. DasGupta, S., Murumkar, P.R., Giridhar, R. & Yadav, M.R. Current perspective of TACE inhibitors: a review. Bioorg. Med. Chem. 17, 444-459 (2009).
18. Nuti, E., Tuccinardi, T. & Rossello, A. Matrix metalloproteinase inhibitors: new challenges in the era of post broad-spectrum inhibitors. Curr. Pharm. Des. 13, 2087-2100 (2007).
19. Lahm, A. et al. Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc. Natl. Acad. Sci, USA 104, 17335-17340 (2007).
20. Baloglu, E., Ghosh, S., Lobera, M. & Schmidt, D.R. Compounds and Methods. US Provisional Patent Application PCT/US2011/021089 (2011).
21. Ma, X., Ezzeldin, H.H. & Diasio, R.B. Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs 69, 1911-1934 (2009).
22. Dormán, G. et al. Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility. Drugs 70, 949-964 (2010).
23. Schuetz, A. et al. Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity. J. Biol. Chem. 283, 11355-11363 (2008).
24. Bottomley, M.J. et al. Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain. J. Biol. Chem. 283, 26694-26704 (2008).
25. Allen, F.H. The Cambridge Structural Database: a quarter of a million crystal structures and rising. Acta Crystallogr. B 58, 380-388 (2002).
26. Bantscheff, M. et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat. Biotechnol. 29, 255-265 (2011).
27. Bertos, N.R., Wang, A.H. & Yang, X.J. Class II histone deacetylases: structure, function, and regulation. Biochem. Cell Biol. 79, 243-252 (2001).
28. Emanuele, S., Lauricella, M. & Tesoriere, G. Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review). Int. J. Oncol. 33, 637-646 (2008).
29. Fleetwood, A.J., Lawrence, T., Hamilton, J.A. & Cook, A.D. Granulocyte-macrophage colony-stimulating factor (CSF) and macrophage CSF-dependent macrophage phenotypes display differences in cytokine profiles and transcription factor activities: implications for CSF blockade in inflammation. J. Immunol. 178, 5245-5252 (2007).
30. Lacey, D.C. et al. Defining GM-CSF-and macrophage-CSF-dependent macrophage responses by in vitro models. J. Immunol. 188, 5752-5765 (2012).
31. Parra, M. & Verdin, E. Regulatory signal transduction pathways for class IIa histone deacetylases. Curr. Opin. Pharmacol. 10, 454-460 (2010).
32. Spiegel, S., Milstien, S. & Grant, S. Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene 31, 537-551 (2012).
33. Kewitz, S., Bernig, T. & Staege, M.S. Histone deacetylase inhibition restores cisplatin sensitivity of Hodgkin's lymphoma cells. Leuk. Res. 36, 773-778 (2012).